Abaucin

Last updated

Abaucin
Abaucin.svg
Identifiers
  • 1'-[2-[4-(trifluoromethyl)phenyl]ethyl]spiro[1H-3,1-benzoxazine-4,4'-piperidine]-2-one
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEBI
ChEMBL
Chemical and physical data
Formula C21H21F3N2O2
Molar mass 390.406 g·mol−1
3D model (JSmol)
  • C1CN(CCC12C3=CC=CC=C3NC(=O)O2)CCC4=CC=C(C=C4)C(F)(F)F
  • InChI=1S/C21H21F3N2O2/c22-21(23,24)16-7-5-15(6-8-16)9-12-26-13-10-20(11-14-26)17-3-1-2-4-18(17)25-19(27)28-20/h1-8H,9-14H2,(H,25,27)
  • Key:HIDWEYPGMLIQSN-UHFFFAOYSA-N

Abaucin (RS-102895, MLJS-21001) is a spirocycle containing substituted phenethylamine that has been reported to show useful activity as a narrow-spectrum antibiotic. [1] There is evidence that it is effective against Acinetobacter baumannii , which is one of three bacterial species identified by the World Health Organization as a "critical threat" to humanity. Notably, abaucin was developed with assistance from artificial intelligence by a team led by the MIT Jameel Clinic's faculty lead for life sciences, James J. Collins, and McMaster's Jonathan Stokes. [2] [3] [4] Its mode of action involves inhibiting lipoprotein transport. The compound had previously been reported as an antagonist of the chemokine receptor CCR2, but the molecule's antibiotic activity was not discovered until 2023. [5] [6] [7] [8] [9]

A New York Times opinion piece by Peter Coy for Thanksgiving listed abaucin among scientific discoveries to be thankful for in 2023. [10]

See also

References

  1. ↑ Liu G, Catacutan DB, Rathod K, Swanson K, Jin W, Mohammed JC, et al. (May 2023). "Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii". Nature Chemical Biology. 19 (11): 1342–1350. doi:10.1038/s41589-023-01349-8. PMID   37231267. S2CID   258909341.
  2. ↑ Gallagher J (May 25, 2023). "New superbug-killing antibiotic discovered using AI". BBC News.
  3. ↑ Trafton A (25 May 2023). "Using AI, scientists find a drug that could combat drug-resistant infections". MIT News . Retrieved 28 May 2023.
  4. ↑ "Scientists use AI to find promising new antibiotic to fight evasive hospital superbug". McMaster University. 25 May 2023.
  5. ↑ Clark RD, Caroon JM, Kluge AF, Repke DB, Roszkowski AP, Strosberg AM, et al. (May 1983). "Synthesis and antihypertensive activity of 4'-substituted spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-ones". Journal of Medicinal Chemistry. 26 (5): 657–661. doi:10.1021/jm00359a007. PMID   6842505.
  6. ↑ Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, et al. (August 2000). "Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle". The Journal of Biological Chemistry. 275 (33): 25562–25571. doi: 10.1074/jbc.M000692200 . PMID   10770925.
  7. ↑ Rehni AK, Singh N (March 2012). "Ammonium pyrrolidine dithiocarbamate and RS 102895 attenuate opioid withdrawal in vivo and in vitro". Psychopharmacology. 220 (2): 427–438. doi:10.1007/s00213-011-2489-8. PMID   21931991. S2CID   253752924.
  8. ↑ Yuan F, Yosef N, Lakshmana Reddy C, Huang A, Chiang SC, Tithi HR, Ubogu EE (2014). "CCR2 gene deletion and pharmacologic blockade ameliorate a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome". PLOS ONE. 9 (3): e90463. Bibcode:2014PLoSO...990463Y. doi: 10.1371/journal.pone.0090463 . PMC   3954548 . PMID   24632828.
  9. ↑ Alsheikh AJ, Dasinger JH, Abais-Battad JM, Fehrenbach DJ, Yang C, Cowley AW, Mattson DL (April 2020). "CCL2 mediates early renal leukocyte infiltration during salt-sensitive hypertension". American Journal of Physiology. Renal Physiology. 318 (4): F982 –F993. doi:10.1152/ajprenal.00521.2019. PMC   7191447 . PMID   32150444.
  10. ↑ Coy P (2023-11-24). "Opinion | What Am I Thankful for This Year? Amazing Scientific Discoveries". The New York Times. ISSN   0362-4331 . Retrieved 2023-11-26.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.